Week Ending February 22, 2022

Busting Myths Related to Lung Cancer
“According to the Centers for Disease Control and Prevention (CDC), lung cancer is the third most common cancer in the US and has led to a number of deaths. Lung cancer is also one of the leading health concerns due to growing misconceptions, myths, and lack of funds for treatment.”

Hanna Discusses Efficacy Results of Different Treatments in RET-Positive Lung Cancer
“During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.”

Kentucky has high rate of lung disease; see KET’s 3-part series ‘Fighting to Breathe’ starting tomorrow
When it comes to lung health, Kentucky has its challenges.”

COVID-19 pandemic significantly reduced lung cancer clinical trial enrollment
“Enrollment in lung cancer clinical trials declined 14 percent during the COVID-19 pandemic, according to research published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.”

New blood test can detect lung cancer with high accuracy, study says
“In 90 minutes, a new rapid blood test can detect the early stages of lung cancer with high accuracy, according to a new study.”

SIUH experts warn FDNY retirees to get screened for lung cancer
STATEN ISLAND, N.Y. — “Firefighters, due to the nature of the job, are susceptible to develop specific injuries, health problems and certain diseases as a result of their career.”

New Drug Application for Adagrasib Accepted by FDA for KRAS G12C+ NSCLC
“The FDA has accepted a new drug application (NDA) for adagrasib (MRTX 849) as treatment for patients with previously treated KRAS G12C–positive non–small cell lung cancer (NSCLC), according to a press release from drug developer Mirati Therapeutics.1

PRO-Based Symptom Management Improves Post discharge Outcomes After Lung Cancer Surgery
“Patients who utilized a patient-reported outcome (PRO) symptom measurement tool reported superior post-discharge outcomes after lung cancer surgery compared with those who received usual care.”

What to Know About Clinical Trials for Lung Cancer
“Clinical trials are studies that help researchers find new ways to prevent, diagnose, or treat diseases. They are the primary way that scientists determine if new treatments are safe and effective.1 However, there are also risks, such as the potential to receive a therapy that doesn’t help you.”

CMS Expands Medicare Eligibility for CT Lung Cancer Screening
“In a new national coverage determination, the Centers for Medicare and Medicaid Services (CMS) have lowered the starting thresholds for lung cancer screening from 55 to 50 years of age and from a 30-pack/year tobacco smoking history to 20 packs a year.”

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics’ New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
“Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022.”